Business Update
Coley Pharmaceutical Group updates hepatitis C drug development strategy
Published in Hepatitis Weekly, February 19th, 2007
Coley will focus its resources towards discovering and developing new TLR Therapeutics, including its preclinical pipeline of synthetic RNA-based drugs designed to stimulate Toll-like receptors (TLRs) 7 and 8, as well as other synthetic agonists and antagonists targeting TLRs 7, 8 and 9.
"The decision to suspend a drug development program is a difficult one," commented Robert L. Bratzler, PhD, president and chief executive...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-02-19)
More Articles from Hepatitis Weekly
- Hepatitis C Virus
Nabi initiates phase 2 proof-of-concept trial of Civacir in HCV-related liver disease - Cancer Gene Therapy
Research from University of Thessaly, Department of Biology has provided new information about cancer gene therapy - Cancer Vaccines
Data on cancer vaccines published by researchers at University of Cologne, Institute of Virology - Hepatitic B Vaccines
Research on hepatitic b vaccines published by scientists at Tehran University of Medical Sciences, Department of Gastroenterology - Hepatitic B Vaccines
Studies from Ataturk Education and Training Hospital describe new findings in hepatitic b vaccines - Hepatitis A Vaccines
Medical University of Vienna details research in hepatitis a vaccines - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
